ZebraSci is excited to announce that we will be attending the 2018 Drug Delivery Partnerships (DDP) conference in Florida from January 22-24 to present our innovative drug delivery device development solutions.

“The conference brings together industry and regulatory experts to share their experiences and explore new developments, regulatory considerations, trends and best practices for the design, development and commercialization of drug delivery devices,” said Eric Creveling, Director of Lab Services at ZebraSci.

ZebraSci works in partnership with our clients, working to ensure that their primary packaging and container systems meet existing and proposed regulatory requirements. With our network of resources, ZebraSci’s experienced team can help you select primary containers, establish device performance specifications, develop design verification testing plans and execute all the required testing. Our complaint handling and root cause analysis programs help you manage your device post-launch. Our consultative approach and highly-developed validation and qualification procedures, ensure that your device comes to market on time, on budget and in compliance with ISO 13485 and FDA 21 CFR 820.

Whether you’re interested in device engineering, regulatory, human factors or you’d just like to learn more about ZebraSci, let’s connect at DDP! Give us a call or email sales@zebrasci.com to set-up a specific time to meet this January.

About ZebraSci – From Concept to Commercialization

ZebraSci Inc. was founded in 2009 as a company dedicated to developing novel inspection technologies to ensure quality in parenteral packaging and combination products. Over the years, we’ve grown substantially and by concentrating on scientific expertise, customer service and a strict adherence to regulatory compliance, ZebraSci now works with 100’s of medical device manufacturers – many in the Fortune 500 Pharmaceutical and Biotechnology Companies. Our clients partner with ZebraSci to resolve technical issues and accelerate “time to market” to support the development of safe and effective combination products for commercialization around the globe.